Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Geiger-Gritsch, S; Olschewski, H; Kocher, F; Wurm, R; Absenger, G; Flicker, M; Hermann, A; Heininger, P; Fiegl, M; Zechmeister, M; Endel, F; Wild, C; Pall, G.
Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Wien Klin Wochenschr. 2021; 133(21-22):1122-1130 Doi: 10.1007/s00508-021-01940-w
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Absenger Gudrun
Olschewski Horst
Wurm Robert

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

OBJECTIVE: As real-world data regarding immunotherapy for non-small cell lung cancer are lacking for Austria, we conducted a retrospective study in six hospitals to present data from real-world practice. METHODS: Patients with metastatic non-small cell lung cancer were stratified into two groups, either patients with first-line pembrolizumab monotherapy (cohort 1) or patients with second-line nivolumab, pembrolizumab or atezolizumab monotherapy (cohort 2). Primary outcome measures were objective response rate and overall survival. A matched-pair analysis was performed to compare overall survival to patients from the Tyrolean Lung Cancer Project as a historical control group. RESULTS: In total, 89 patients were identified, 42 patients in cohort 1 and 47 patients in cohort 2. The objective response rates were 43.3% and 31.4%, respectively. The median overall survival was 17.0 months (95% CI 11.7-21.5 months) in cohort 1 and 18.7 months (95% CI 9.5-23.4 months) in cohort 2. Treatment-related adverse events grades 3 and 4 were reported in 11.2% of patients. The matched-pair analysis showed a median overall survival of 15.2 months (95% CI 7.6-20.4 months) for first-line pembrolizumab monotherapy compared to 9.8 months (95% CI 7.8-11.6 months) for the historical control (p = 0.43). In cohort 2, a median overall survival of 20.3 months (95% CI 6.9-26.2 months) for second-line immunotherapy compared to 5.4 months (95% CI 3.2-11.7 months) for the historical control (p = 0.18) was shown. CONCLUSION: The results are comparable with other real-world studies and, when matched to historical controls, support the improvement in outcomes made possible by these agents.
Find related publications in this database (using NLM MeSH Indexing)
Austria - administration & dosage
B7-H1 Antigen - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Humans - administration & dosage
Lung Neoplasms - drug therapy
Retrospective Studies - administration & dosage

Find related publications in this database (Keywords)
Non-small cell lung cancer
Immune checkpoint inhibitors
© Med Uni Graz Impressum